Mark A. Velleca
2023 - Black Diamond Therapeutics
In 2023, Mark A. Velleca earned a total compensation of $2.9M as President and Chief Executive Officer at Black Diamond Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $113,667 |
---|---|
Option Awards | $2,591,404 |
Salary | $180,333 |
Other | $63,950 |
Total | $2,949,854 |
Velleca received $2.6M in option awards, accounting for 88% of the total pay in 2023.
Velleca also received $113.7K in non-equity incentive plan, $180.3K in salary and $64K in other compensation.
Rankings
In 2023, Mark A. Velleca's compensation ranked 309th out of 2,821 executives tracked by ExecPay. In other words, Velleca earned more than 89.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 309 | 89th |
Manufacturing | 171 | 89th |
Chemicals And Allied Products | 116 | 87th |
Drugs | 113 | 87th |
Biological Products, Except Diagnostic Substances | 39 | 81st |
Velleca's colleagues
We found three more compensation records of executives who worked with Mark A. Velleca at Black Diamond Therapeutics in 2023.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019